<DOC>
	<DOCNO>NCT01966445</DOCNO>
	<brief_summary>Human Epidermal Growth Factor Receptor 3 ( HER3 ) expression see across wide variety solid malignancy associate poor prognosis . Up-regulation HER3 expression activity also associate resistance multiple pathway inhibitor . GSK2849330 , monoclonal antibody target HER3 , new agent subject whose tumor express HER3 . This study phase I , first time human , open-label , dose escalation study . The purpose study investigate safety , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) GSK2849330 subject advance HER3-positive solid tumor . The study conduct two part . Part 1 ( Dose-Escalation Phase ) include dose escalation PK/PD cohorts evaluate safety , PK , PD guide selection dose regimen ( ) Part 2 . In Part 2 ( Expansion Cohorts ) , 3 cohort enrol dose regimen ( ) select base Part 1 data , evaluate safety large cohort subject recommend dose regimen also evaluate preliminary evidence clinical benefit .</brief_summary>
	<brief_title>Dose Escalation Study Investigate Safety , Pharmacokinetics , Pharmacodynamics GSK2849330 Subjects With Advanced Her3-Positive Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Males female &gt; =18 year age ( time consent obtain ) . Written inform consent provide . Performance Status score 0 1 accord Eastern Cooperative Oncology Group ( ECOG ) scale . Sufficient archival tumor specimen available HER3 immunohistochemistry ( IHC ) analysis , subject willing undergo fresh tumor biopsy HER3 IHC analysis . Histologically cytologically confirm diagnosis one follow solid tumor malignancy standard therapeutic alternative exist : bladder cancer , breast cancer , castrateresistant prostate cancer , cervical cancer , colorectal cancer ( CRC ) , gastric cancer , hepatocellular carcinoma ( HCC ) , melanoma , nonsmall cell lung cancer ( NSCLC ) , ovarian cancer , pancreatic cancer , squamous cancer head neck region ( include parotid nasopharynx ) . Subjects leptomeningeal brain metastasis spinal cord compression . Prior HER3 direct treatment ( HER2 EGFRdirected treatment acceptable ) . Concurrent medical condition would jeopardize compliance . Receiving chronic immunosuppressive therapy ( include daily steroid dos excess 20 milligram [ mg ] /day prednisone ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>GSK2849330</keyword>
	<keyword>Oncology</keyword>
	<keyword>First Time Human</keyword>
	<keyword>HER3</keyword>
</DOC>